Pasithea Therapeutics announced promising preclinical data for PAS-004, a next-generation MEK inhibitor, which shows superior effectiveness in inhibiting the ETS2 pathway associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results